Companies/DIAGNOS Inc.

Company profile

DIAGNOS Inc.

OTC: DGNOF · Healthcare · Medical - Healthcare Information Services

Canadian filerHQ Brossard, QCReports USD

#1069 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

29D

FH 23DQ —GM 31SS 57

v0.1 · 45/100 weight · provisional

↑ listing tenure, growth stability · ↓ return on equity, operating margin

Methodology →

Revenue TTM

$47.4k

Rev growth YoY (TTM)

-36.7%

Net income (FY)

-$3.3M

Employees

Market cap

$18.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$47.5k65.6k CAD2026

Net income-$3.3M-4.6M CAD2026

Operating income-$3.1M-4.3M CAD2026

Total assets$1.7M2.4M CAD2026

Liabilities$1.2M1.7M CAD2026

Equity$494.1k688.7k CAD2026

Revenue trend

FY2019 – FY2026 · USD

$248.9k

FY19

$245.3k

FY20

$250.7k

FY21

$213.0k

FY22

$331.8k

FY23

$126.2k

FY24

$74.6k

FY25

$47.5k

FY26

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

DIAGNOS Inc. booked $47.5k in FY2026 revenue, contracting 36% year over year — slower than 78% of Healthcare companies we track, at a -6957.0% net margin.

Peers · Healthcare

Harvard Apparatus Regenerative Technology Inc.42D Neuphoria Therapeutics Inc.44D Atossa Therapeutics, Inc.29D Defence Therapeutics Inc.——

Key facts

CEOAndre Larente

SectorHealthcare

IndustryMedical - Healthcare Information Services

HeadquartersBrossard, QC

ExchangeOTC: DGNOF

Employees22

IPO date2003-06-24

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.